A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

A Phase 2b Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

This is a multicenter, open-label, Phase 2b study to evaluate the efficacy and safety of 2 LB SQ injections administered at a 4-month (approximately 17 weeks) interval for female contraception.

Study Overview

• Status: Not yet recruiting
• Conditions: Female Contraception; Healthy Women
• Intervention / Treatment: Drug: Levonorgestrel butanoate

Detailed Description

This is a multicenter, open-label, Phase 2b study to evaluate the efficacy and safety of 2 LB SQ injections administered at a 4-month (approximately 17 weeks) interval for female contraception. The study plans to enroll approximately 165 female participants, 18 to 35 years of age, inclusive, at enrollment (Visit 2, Day 1), who have good general overall health. They also must have menstrual cycles of 21 to 35 days when not using hormonal contraception with typical variation in cycle length of 5 days or less, have an intact uterus and at least 1 ovary, expect to have heterosexual intercourse at least once per month during the study, and agree to use no additional methods of contraception during the study. Participants will be excluded if they are planning pregnancy during study participation through the End-of-Treatment Visit (Visit 11, Day 240). In addition, participants must have had 2 spontaneous menses (1 cycle) since delivery, 1 menses following first or second trimester abortion or miscarriage, must not be breastfeeding, or be within 30 days of discontinuing breastfeeding unless the participant has already had 1 cycle (2 menses) following discontinuation of breastfeeding.

The primary aim of the study is to evaluate the contraceptive efficacy of LB SQ injections over 8 cycles. Additionally, LB safety will be assessed based on the incidence of AEs (including weight increase) and injection site reactions and changes from baseline laboratory parameters. The number of bleeding and spotting days per 30-, 90-, and 120-day intervals, as well as responses from the acceptability and satisfaction questionnaire at Day 240 (Month 8), are also secondary endpoints of the study.

• Study Type: Interventional
• Enrollment (Estimated): 165
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Lauren Schumacher; Phone Number: 984-569-6827; Email: Lauren.Schumacher@premier-research.com
• Study Contact Backup: Name: Carly Shabshelowitz; Phone Number: 919-695-6177; Email: carly.shabshelowitz@premier-research.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Participant understands and signs an ICF approved by the institutional review board prior to any screening activities.
2. Female and 18 to 35 years of age, inclusive, at enrollment (Visit 2, Day 1).
3. Good general overall health with no chronic medical conditions that result in periodic exacerbations requiring significant medical care.
4. Menstrual cycles of 21 to 35 days in length with typical variation in cycle length of 5 days or less when not using hormonal contraception.
5. Intact uterus and at least 1 ovary.

6. If used a hormonal contraceptive or intra-uterine device (IUD) prior to enrollment, the participant meets the appropriate criteria for time since last use:

   1. Oral, transdermal, vaginal, copper or LNG IUD or implantable hormonal contraceptives: participants must have discontinued hormone use ≥4 days prior to start of study treatment, experienced bleeding that is consistent with menses in the opinion of the investigator and not have had unprotected intercourse since discontinuing the method.
   2. Injectable contraception (e.g., DMPA): No injection during the 10 months prior to the Screening Visit, unless the participant has returned to normal menses (i.e., 2 consecutive menses) since last injection.
7. Negative urine pregnancy test at enrollment (Visit 2, Day 1).
8. Body mass index <40 kg/m2.
9. Willing to use the study method as the primary method of contraception until the end of the Treatment Period.

10. At risk for pregnancy defined as:

    1. Expecting to have ≥1 act of heterosexual intercourse each month during study participation until the end of the Treatment Period.
    2. No medical history suggesting possible infertility or hypofertility, including but not limited to, ectopic pregnancy or pelvic infection (unless has had a subsequent intra-uterine pregnancy).
    3. Has a sexual partner with no known problems with infertility orhypofertility.

Exclusion Criteria:

1. Planning pregnancy during study participation through the End -of -Treatment Visit (Visit 11, Day 240).
2. Is post-partum and has not had 2 spontaneous menses (1 cycle) since delivery or 1 menses since first or second trimester abortion or miscarriage.
3. Breastfeeding or within 30 days of discontinuing breastfeeding unless the participant has already had 2 menses (1 cycle) following discontinuation of breastfeeding.
4. Undiagnosed abnormal genital bleeding.
5. Undiagnosed vaginal discharge, lesions, or abnormalities.
6. Participating in another clinical study involving an IP or device within 30 days prior to the Screening Visit or planning to participate in another clinical study during this study.
7. Not living in the catchment area of the study site.
8. Known hypersensitivity or contraindication to progestins, including the active substance LB or any excipients of the study treatment.
9. Current need for therapeutic anticoagulation or known history of thrombophilia.
10. Use or planned use of exogenous reproductive hormones during study participation.
11. Body weight change exceeding 10% over the previous year or planned significant weight loss during the study related to bariatric surgery, dieting, or planned treatment.
12. Uncontrolled hypertension, in which diastolic blood pressure remains ≥95 mmHg or systolic blood pressure remains ≥145 mmHg.

13. Smoking nicotine (e.g., cigarettes or electronic cigarettes) AND has at least 1 of the following comorbidities or conditions (at the discretion of the investigator):

    • Current or history of venous thrombophlebitis or thromboembolic disorders (including deep vein thrombosis and pulmonary embolism).
    • Current or history of cerebrovascular or coronary-artery disease.
    • Valvular heart disease with thrombogenic complications.
    • Diabetes with vascular involvement.
    • Known inherited or acquired predisposition to venous thromboembolism or arterial thromboembolism (e.g., factor VLeiden, prothrombin mutation, antiphospholipid antibodies) or bruising within the last 12 months prior to consent.
14. Current or past cerebrovascular or cardiovascular disease or at risk of clotting disorders.
15. Impaired mobility (e.g., is wheelchair bound or bedridden) that, in the investigator's opinion, places the participant at increased risk of thrombosis.
16. Known or suspected carcinoma of the breast or suspected progestin-dependent neoplasia.
17. Known or suspected pelvic organ carcinoma.
18. Known Papanicolaou (Pap) or human papillomavirus (HPV) test abnormality that would require a repeat evaluation or treatment during study participation based on standard of care guidelines (American Society for Colposcopy and Cervical Pathology or American College of Obstetricians and Gynecologists).
19. Known benign or malignant liver tumors, renal disease, or active liver disease.
20. Invasive cancer (past history of any carcinoma or sarcoma, except non-melanoma skin cancer) unless in remission for >5 years.
21. Current or past medically diagnosed severe depression, which, in the investigator's opinion, could be exacerbated by use of a hormonal contraceptive, unless participant is on stable antidepressant medication.
22. Known or suspected current alcohol dependence syndrome or any recreational drug use that may affect metabolism of the IP or study compliance.

23. Abnormal screening laboratory values defined as:

    1. Fasting clinical chemistry values or CBC values designated clinically significant by the investigator.
    2. Liver function test results >twice the upper limit of normal.
24. Uncontrolled thyroid disorder.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LB 60 mg SQ (70 mg/mL); The participants will receive 2 injections of LB 60 mg SQ (70 mg/mL); 1 at Visit 2 (Day 1) and 1 at Visit 7 (Day 120).	Drug: Levonorgestrel butanoate; 60 mg SQ (70 mg/mL); Other Names: Chemical, Generic: 13β-ethyl-17α-ethynylgon-4-en-3-one- 17β-n-butyrate; Trade Names: CDB-1830 and HRP002

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the contraceptive efficacy of 2 LB SQ injections administered at a 4-month (approximately 17 weeks)interval over 8 cycles	As measured by The cumulative pregnancy percentage (calculated using Kaplan-Meier) through 8 cycles	224 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the safety of 2 LB SQ injections	To assess the safety of 2 LB SQ injections as measured by: Number of participants with abnormal laboratory values and/or adverse events that are related to treatment	240 days
To further explore the contraceptive efficacy of 2 LB SQ injections	To further explore the contraceptive efficacy of 2 LB SQ injections as measured by the Pearl Index through 8 cycles	224 days
To explore bleeding patterns in participants receiving 2 LB SQ injections	To explore bleeding patterns in participants receiving 2 LB SQ injections as measured by Number of bleeding and spotting days per 30-, 90-, and 120-day intervals	240 days
To evaluate acceptability of 2 LB SQ injections	To evaluate acceptability of 2 LB SQ injections as measured by the number and percentage of subjects that provide each response to a given question related to acceptability on the CCN021b Acceptability and Satisfaction Questionnaire responses at 8 months. Questions range from 'Definitely No' to 'Definitely Yes'.	240 days
To evaluate satisfaction of 2 LB SQ injections	To evaluate satisfaction of 2 LB SQ injections as measured by the number and percentage of subjects that provide each response to a given question related to satisfaction on the CCN021b Acceptability and Satisfaction Questionnaire responses at 8 months. Questions range from 'Very Satisfied' to 'Very Unsatisfied' and 'Strongly Agree' to 'Strongly Disagree'.	240 days

Collaborators and Investigators

• Sponsor: Premier Research
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Investigators: Study Director: Diana Blithe, PhD, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): March 31, 2029

Study Registration Dates

• First Submitted: October 22, 2025
• First Submitted That Met QC Criteria: October 27, 2025
• First Posted (Estimated): October 29, 2025

Study Record Updates

• Last Update Posted (Estimated): October 29, 2025
• Last Update Submitted That Met QC Criteria: October 27, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: Female contraception
• Additional Relevant MeSH Terms: levonorgestrel butanoate
• Other Study ID Numbers: CCN021B

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No